Marketing-authorisation holder
Eisai Ltd
25 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
25 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
25 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BANZEL400 mg · Tablet | Rufinamide | Canada | Marketed | 2011 |
| BANZEL100 mg · Tablet | Rufinamide | Canada | Marketed | 2011 |
| BANZEL200 mg · Tablet | Rufinamide | Canada | Marketed | 2011 |
| DAYVIGO5 mg · Tablet | Lemborexant | Canada | Marketed | 2020 |
| DAYVIGO10 mg · Tablet | Lemborexant | Canada | Marketed | 2020 |
| FYCOMPA12.0 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| FYCOMPA8.0 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| FYCOMPA2 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| FYCOMPA10.0 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| FYCOMPA4.0 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| FYCOMPA6.0 mg · Tablet | Perampanel | Canada | Marketed | 2013 |
| HALAVEN0.5 mg / ml · Solution | Eribulin | Canada | Marketed | 2012 |
| LENVIMA20 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2016 |
| LENVIMA14 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2016 |
| LENVIMA4 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2019 |
| LENVIMA10 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2016 |
| LENVIMA8 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2018 |
| LENVIMA12 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2019 |
| LENVIMA24 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2016 |
| LENVIMA18 mg / dose · Capsule | Lenvatinib | Canada | Marketed | 2018 |
| LEQEMBI100 mg / ml · Solution | Lecanemab | Canada | Marketed | 2025 |
| BANZEL40 mg / ml · Suspension | Rufinamide | Canada | Cancelled | |
| FYCOMPA0.5 mg / ml · Suspension | Perampanel | Canada | Cancelled | |
| GLIADEL WAFER7.7 mg · Wafer | Carmustine | Canada | Cancelled | 2002 |
| HEXALEN50 mg · Capsule | Altretamine | Canada | Cancelled | 1995 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 25 | 21 | 4 | CompaniesAll medicines |
Also in the registers of Spain, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.